SOURCE: SpectraScience, Inc.

SpectraScience, Inc.

June 02, 2015 09:15 ET

SpectraScience's WavSTAT4 Results Presented at Digestive Disease Week (DDW)

SAN DIEGO, CA--(Marketwired - Jun 2, 2015) -  SpectraScience, Inc. (OTCQB: SCIE), a medical device company utilizing light technologies to detect and diagnose cancers, announced today European researchers recently presented a paper at DDW, the world's largest Gastroenterology meeting, held in Washington, D.C. in May. The results of the paper showed the accuracy of the WavSTAT4R Optical Biopsy System exceeded the guideline of 90% Negative Predictive Value (NPV) put forth by the American Society for Gastrointestinal Endoscopy (ASGE). With an overall NPV of 96% across the entire colon and 98% in the recto-sigmoid colon, the WavSTAT4 Optical Biopsy System was found " be accurate enough to leave distal colorectal polyps in place without resection or to resect and discard them without pathologic assessment." The paper went on to conclude that the WavSTAT4 system has the potential to reduce costs and risks associated with the redundant removal of certain colorectal polyps.

"These results highlight the key elements of our value proposition- safer for the patient, faster for the doctor or nurse practitioner, and less expensive for the health care system- and provide the clinical validation of our technology," stated Michael Oliver, President and Chief Executive Officer. "With this clinical validation of the economic savings inherent in the reduction of unnecessary pathology costs and patient complications, we now have the necessary proof to begin our sales and marketing activities throughout Europe." 

About SpectraScience, Inc.:

SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use.

For more information:

Visit our web site  

Forward-Looking Statement for SpectraScience, Inc.

This news release contains forward-looking statements that involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.

Contact Information

  • Contacts:
    Media and Investors:
    SpectraScience, Inc.
    Lowell Giffhorn
    Phone: (858) 847-0200 x2019
    Email: Email Contact